NCT03338907

Brief Summary

Several projects in high altitude research in environments with a low oxygen partial pressure (hypobaric hypoxia) leading to hypoxemia showed, that cerebral perfusion and cerebral performance could be improved by adding C02 (cabon dioxide). The investigators hypothesize that adding 5% C02 to 02 (Oxygen) also under normobaric conditions increases the time until a significant cerebral hyopxia is measured by near infrared spectroscopy (NIRS) compared to the administration of 95% 02. lf this hypothesis proves to be true, this approach might be used in situations in which individuals are prone to cerebral hypoxia. In bariatric surgery, patients that experience an apnea phase are more prone to (cerebral) hypoxia due to the fact, that they have a higher body mass index (BMI) leading to a reduced functional residual capacity (FRC), which serves as the oxygen reserve in the body.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jan 2018

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 30, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 9, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

January 25, 2018

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 26, 2018

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 12, 2019

Completed
Last Updated

February 20, 2019

Status Verified

February 1, 2019

Enrollment Period

9 months

First QC Date

October 30, 2017

Last Update Submit

February 19, 2019

Conditions

Keywords

cerebral hypoxiaCO2cerebral perfusionhypoxia

Outcome Measures

Primary Outcomes (1)

  • Time to decrease of tissue oxygenation index by 20 %

    Parameter will be measured by NIRS

    1 Day

Secondary Outcomes (3)

  • PaO2 (Oxygen partial pressure)

    1 Day

  • SpO2 (oxygen saturation)

    1 Day

  • PCO2 ( partial pressure of carbon)

    1Day

Study Arms (2)

Oxycarbon (5% CO2 + 95% O2)

EXPERIMENTAL

Patients will be mechanical ventilated with Oxycarbon (5%CO2 +95% O2) after normocapnia is reached until FeO2 is stable for at least 1 min ≥ 80%. At timepoint 1 immediately prior apnea NIRS and vital parameters will be registered and an bloodsample will be drawn.

Drug: Oxycarbon (5% CO2+ 95% O2)

Control (95% O2)

PLACEBO COMPARATOR

Same procedure as arm "active comparator"

Drug: Oxycarbon (5% CO2+ 95% O2)

Interventions

Oxycarbon will be administered by mechanical ventilation

Control (95% O2)Oxycarbon (5% CO2 + 95% O2)

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who are designated for bariatric surgery at the University Hospital Zurich (USZ)
  • Informed Consent as documented by signature
  • BMI \>35 kg/m2

You may not qualify if:

  • Severe end-organ damage: chronic obstuctive pulmonary disease (COPD) GOLD (cassification) III and IV, known hepatic insufficiency or elevated liver enzymes, renal creatinine clearance \<30ml/min
  • Severe cardiovascular disease (NYHA classification III and IV)
  • Known pulmonary Hypertension
  • Cerebrovascular disease
  • Pregnancy and lactation
  • Cardiac dysrhythmias
  • acidosis, chronic pulmonary disease
  • Known or suspected non-compliance, drug or alcohol abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Zurich

Zurich, Switzerland

Location

Related Publications (6)

  • Kety SS, Schmidt CF. THE EFFECTS OF ALTERED ARTERIAL TENSIONS OF CARBON DIOXIDE AND OXYGEN ON CEREBRAL BLOOD FLOW AND CEREBRAL OXYGEN CONSUMPTION OF NORMAL YOUNG MEN. J Clin Invest. 1948 Jul;27(4):484-92. doi: 10.1172/JCI101995. No abstract available.

    PMID: 16695569BACKGROUND
  • Karl AA, McMillan GR, Ward SL, Kissen AT, Souder ME. Effects of increased ambient CO2 on brain tissue oxygenation and performance in the hypoxic rhesus. Aviat Space Environ Med. 1978 Aug;49(8):984-9.

    PMID: 98161BACKGROUND
  • Brzecka A. Role of hypercapnia in brain oxygenation in sleep-disordered breathing. Acta Neurobiol Exp (Wars). 2007;67(2):197-206. doi: 10.55782/ane-2007-1648.

    PMID: 17691228BACKGROUND
  • Kronenberg RS, Drage CW. Attenuation of the ventilatory and heart rate responses to hypoxia and hypercapnia with aging in normal men. J Clin Invest. 1973 Aug;52(8):1812-9. doi: 10.1172/JCI107363.

    PMID: 4719663BACKGROUND
  • Hannay DR, Maddox EJ. Symptom prevalence and referral behaviour in Glasgow. Soc Sci Med (1967). 1976 Mar-Apr;10(3-4):185-9. doi: 10.1016/0037-7856(76)90046-9. No abstract available.

    PMID: 968505BACKGROUND
  • Ainslie PN, Poulin MJ. Ventilatory, cerebrovascular, and cardiovascular interactions in acute hypoxia: regulation by carbon dioxide. J Appl Physiol (1985). 2004 Jul;97(1):149-59. doi: 10.1152/japplphysiol.01385.2003. Epub 2004 Mar 5.

    PMID: 15004003BACKGROUND

MeSH Terms

Conditions

Hypoxia, BrainHypoxia

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Martin Schläpfer, MD, M.Sc.

    University of Zurich

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
The sequence whether the IMP or the comparator is applied first will be randomly assigned using the web-based randomizer.
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Controlled, randomized, single blind, crossover
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 30, 2017

First Posted

November 9, 2017

Study Start

January 25, 2018

Primary Completion

October 26, 2018

Study Completion

February 12, 2019

Last Updated

February 20, 2019

Record last verified: 2019-02

Data Sharing

IPD Sharing
Will not share

Ist not planned to share data with other researchers

Locations